Vaxdyn
Vaxdyn is dedicated to preventing and alleviating the global health crisis caused by antibiotic-resistant bacteria through the development of safe and effective vaccines. The company collaborates internationally to develop multi-valent vaccines targeting bacterial pathogens, with a focus on high-risk populations and global health impact.
Industries
Nr. of Employees
small (1-50)
Vaxdyn
Parque Ciudad del Conocimiento, Calle Miguel Manaute Humanes s/n, Edificio central, despacho 6, 41704 Dos Hermanas (Sevilla) SPAIN
Patents
Vaccine against Acinetobacter baumannii based on cellular components deficient in lipopolysaccharide
US-11160856-B2
View Details
Vaccine against Acinetobacter baumannii based on cellular components deficient in lipopolysaccharide
US-11160856-B2
View DetailsProducts
AcinetoVax (VXD001)
An inactivated, LPS‑null (endotoxin‑free) whole‑cell vaccine candidate developed to prevent infections caused by Acinetobacter baumannii.
KapaVax (VXD005)
An inactivated, LPS‑null whole‑cell vaccine candidate based on A. baumannii cells engineered to display conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae on the cell surface.
AcinetoVax (VXD001)
An inactivated, LPS‑null (endotoxin‑free) whole‑cell vaccine candidate developed to prevent infections caused by Acinetobacter baumannii.
KapaVax (VXD005)
An inactivated, LPS‑null whole‑cell vaccine candidate based on A. baumannii cells engineered to display conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae on the cell surface.
Services
Partnerships with academic and industry groups to co‑develop vaccine candidates and progress programs toward clinical or field trial milestones.
Management of grant awards and milestone‑based programs funded by public and philanthropic agencies to advance vaccine candidates.
Partnerships with academic and industry groups to co‑develop vaccine candidates and progress programs toward clinical or field trial milestones.
Management of grant awards and milestone‑based programs funded by public and philanthropic agencies to advance vaccine candidates.
Expertise Areas
- Vaccine development for antibiotic‑resistant bacteria
- Multivalent / multi‑antigen vaccine platforms
- Preclinical development and Phase 1 preparedness
- One‑Health vaccine strategies (human and veterinary)
Key Technologies
- Inactivated whole‑cell vaccines (LPS‑null, endotoxin‑reduced)
- Cell‑surface antigen display
- Multi‑antigen vaccine platform
- Preclinical animal models and field trial readiness
News & Updates
Ten companies headquartered in Andalucía, five from the drugs & diagnostics sector and five from the digital health sector participated in the Investor Day, the closing ceremony…
The experts of the Anti-Microbial Resistance (AMR) world, including Vaxdyn’s researchers, have been warning about the entrance into a post-antibiotic era or the occurrence of a silent…
The project “AMReady: Development and manufacturing of vaccines for alleviation and preparedness for anti-microbial resistance global health crisis”, to be executed in 2021-2024 with a total budget…
In an oral presentation within the track “AMR & Bacterial Vaccines”, chaired by Dr Jan Poolman (Bacterial Vaccine Discovery and Early Development, Janssen), Dr. Infante showed how…
The development of a technology able to deliver multi-pathogen vaccine candidates against the most worrisome antibiotic-resistant bacteria has attracted new investors to Vaxdyn, the Portuguese venture capital…
Vaxdyn’s new vaccine against Gram-negative pathogens, if approved, would help curb the rising threat of drug resistant bacteria SEVILLE, SPAIN – CARB-X is awarding Vaxdyn, based in Seville, Spain, up…
Ten companies headquartered in Andalucía, five from the drugs & diagnostics sector and five from the digital health sector participated in the Investor Day, the closing ceremony…
The experts of the Anti-Microbial Resistance (AMR) world, including Vaxdyn’s researchers, have been warning about the entrance into a post-antibiotic era or the occurrence of a silent…
The project “AMReady: Development and manufacturing of vaccines for alleviation and preparedness for anti-microbial resistance global health crisis”, to be executed in 2021-2024 with a total budget…
In an oral presentation within the track “AMR & Bacterial Vaccines”, chaired by Dr Jan Poolman (Bacterial Vaccine Discovery and Early Development, Janssen), Dr. Infante showed how…
The development of a technology able to deliver multi-pathogen vaccine candidates against the most worrisome antibiotic-resistant bacteria has attracted new investors to Vaxdyn, the Portuguese venture capital…
Vaxdyn’s new vaccine against Gram-negative pathogens, if approved, would help curb the rising threat of drug resistant bacteria SEVILLE, SPAIN – CARB-X is awarding Vaxdyn, based in Seville, Spain, up…